Physician profile
Lee Connor
NPI 1710307129
$14,457.77
in general payments reported to CMS, 2019-2025
34 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $157 · 2021: $393 · 2022: $1,017 · 2023: $4,403 · 2024: $6,157 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,450 · Food and Beverage: $3,108 · Travel and Lodging: $71.40 · Entertainment: $61.62 · Education: $28.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,450.00 |
| Food and Beverage | $3,108.26 |
| Travel and Lodging | $71.40 |
| Entertainment | $61.62 |
| Education | $28.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,717.03 | 2021-2025 | Dalvance, Mavyret, Teflaro |
| Insmed, INC. | $712.37 | 2022-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.78 | 2021-2025 | Ofev |
| Gilead Sciences, INC. | $346.81 | 2021-2025 | |
| Ucb, INC. | $317.79 | 2022-2025 | Cimzia, Bimzelx |
| Allergan, INC. | $282.70 | 2019-2021 | |
| Amgen INC. | $268.36 | 2019-2024 | Enbrel, Otezla, Prolia |
| Melinta Therapeutics, LLC | $223.96 | 2021-2025 | Rezzayo, Kimyrsa, Orbactiv |
| La Jolla Pharmaceutical Company | $198.07 | 2022-2025 | Xerava |
| United Therapeutics Corporation | $157.15 | 2021-2025 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $133.50 | 2023-2024 | Acthar |
| Actelion Pharmaceuticals US, INC. | $70.90 | 2021-2024 | Opsumit |
| Ferring Pharmaceuticals INC. | $69.91 | 2023-2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $69.58 | 2024-2025 | Dupixent |
| Qiagen, LLC | $61.62 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $53.16 | 2021-2022 | |
| Shionogi INC | $44.67 | 2025 | Fetroja |
| Genzyme Corporation | $37.39 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.05 | 2022-2023 | Glassia |
| Merck Sharp & Dohme LLC | $31.82 | 2021-2025 | Capvaxive |
| Tetraphase Pharmaceuticals, INC. | $31.23 | 2025 | |
| Astellas Pharma US INC | $29.57 | 2023 | Cresemba |
| Csl Behring | $22.39 | 2024 | Hizentra |
| Vapotherm INC | $22.29 | 2021 | |
| Baxter Healthcare | $21.02 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Organogenesis INC. | $19.17 | 2024 | Puraply Am |
| Alexion Pharmaceuticals, INC. | $18.47 | 2020 | |
| Verona Pharma, INC. | $18.30 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $17.71 | 2021 | |
| Biomerieux INC | $17.00 | 2025 | Filmarray Bcid Panel |
| Heartflow, INC. | $16.39 | 2025 | |
| Viiv Healthcare Company | $15.87 | 2021 | |
| Advanced Respiratory, INC | $15.36 | 2021 | |
| Mayne Pharma Commercial LLC | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.